No difference in persistence to treatment with atazanavir or darunavir in HIV patients in a real-world setting.

Farr, Amanda M; Johnston, Stephen S; Ritchings, Corey; Brouillette, Matthew; Rosenblatt, Lisa

Farr, Amanda M; Johnston, Stephen S; Ritchings, Corey; Brouillette, Matthew; Rosenblatt, Lisa.

Afiliación

Farr AM; Life Sciences, Truven Health Analytics, Cambridge, MA, USA.
Johnston SS; Life Sciences, Truven Health Analytics, Bethesda, MD, USA.
Ritchings C; US Medical HIV, Bristol-Myers Squibb, Princeton, NJ, USA.
Brouillette M; Life Sciences, Truven Health Analytics, Cambridge, MA, USA.
Rosenblatt L; Health Economics and Outcomes Research, Bristol-Myers Squibb, Plainsboro, NJ, USA.

J Int AIDS Soc ; 17(4 Suppl 3): 19538, 2014.

Article en En | MEDLINE | ID: mdl-25394047

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: J Int AIDS Soc Asunto de la revista: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Año: 2014 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google